In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hepatitis C Marketing: Applying Primary Care Tactics To Specialty Products

Executive Summary

The Food and Drug Administration's back-to-back approvals of Hepatitis C therapies from Merck & Co. and Vertex Pharmaceuticals set the stage for a specialty-focused marketing battle the likes of which the biopharma industry hasn't seen in years.

You may also be interested in...



Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm

With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.

Merck/Roche Co-Promote Pact Attempts To Shut Vertex Out Of HCV Protease Inhibitor Space

Roche will co-promote Merck's Victrelis with its own HCV drugs Pegasys and Copegus in the U.S.

A Few Companies Bet On Continuing Role For Interferon Therapy In HCV

Hepatitis C drug development is almost exclusively focused on small molecule oral therapies. Of the 54 compounds in clinical development, just two aim to improve upon injectable interferon, the molecule that forms the backbone of current standard of care. It would be tempting to write them off, but a funny thing happened on the way to the interferon-free future.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003660

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel